A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis

SMARCA4-deficient thoracic sarcoma (DTS) is a rare malignancy defined by inactivating SMARCA4 mutations leading to protein loss. It was recently described as an aggressive disease with a dismal prognosis, mostly affecting young men with a history of heavy smoking. Histologically, SMARCA4-DTS is a poorly differentiated tumor with rhabdoid or epithelioid features that can be distinguished from other soft tissue, and thoracic sarcomas by a higher tumor mutation burden (TMB) and the presence of smoking signatures, including KRAS, STK11, and KEAP1 mutations. Currently, there is no approved treatment for SMARCA4-DTS, which is known to be chemo-resistant, but more recent studies have shown some effectiveness with immune checkpoint inhibitors. We report the case of a 42-year-old man with a family history of cancer who was admitted to the hospital with acute respiratory distress and superior vena cava syndrome. He had been experiencing thoracic pain, dry cough, dyspnea, fatigue, and unintentional weight loss for a month. Imaging revealed multiple masses and lymph nodes in the chest, as well as pleural effusion. PET scan showed widespread metastases. A cervical lymph node biopsy confirmed the diagnosis of SMARCA4-deficient thoracic sarcoma. Unfortunately, his general condition did not allow an aggressive treatment. He was started on Pazopanib 800mg per day, but deteriorated rapidly and passed away. This report highlights the aggressive nature and unfavorable prognosis associated with SMARCA4-deficient thoracic sarcoma. Accurate diagnosis of this entity can be challenging due to its unique marker expression and unfamiliar histological features. Currently, there are no established treatment strategies for this condition; however, recent studies have shown promising results with immune checkpoint inhibitors and targeted therapies. Further research is necessary to identify the most effective treatment approaches for SMARCA4-DTS.

[1]  Ghassan Al-Shbool,et al.  SMARCA4-Deficient Undifferentiated Tumor: A Rare Malignancy With Distinct Clinicopathological Characteristics , 2022, Cureus.

[2]  T. Murakawa,et al.  SMARCA4‐deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report , 2022, Thoracic cancer.

[3]  F. Bertucci,et al.  Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors , 2022, The oncologist.

[4]  Y. Kukita,et al.  Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. , 2021, Immunotherapy.

[5]  F. Ksontini,et al.  SMARCA4-deficient thoracic sarcoma revealed by metastasis to the small intestine: a diagnostic dilemma , 2021, General Thoracic and Cardiovascular Surgery.

[6]  M. Tsao.  PL01.05 The New WHO Classification of Lung Tumors , 2021 .

[7]  K. Xie,et al.  SMARCA4-deficient uterine sarcoma: A case report and a concise review , 2020, Case reports in women's health.

[8]  S. Ikeda,et al.  Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. , 2020, Immunotherapy.

[9]  David R. Jones,et al.  SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  S. Sugita,et al.  Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report , 2019, Thoracic cancer.

[11]  B. Weissman,et al.  Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities , 2019, Expert review of anticancer therapy.

[12]  Z. Modrušan,et al.  PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors , 2017, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Roden,et al.  SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior , 2017, Modern Pathology.

[14]  T. Kohno,et al.  Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities , 2017, Modern Pathology.

[15]  C. Fletcher,et al.  Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas , 2017, Modern Pathology.

[16]  N. Girard,et al.  SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas , 2015, Nature Genetics.

[17]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[18]  G. Crabtree,et al.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy , 2013, Nature Genetics.

[19]  Stuart H. Orkin,et al.  The SWI/SNF complex — chromatin and cancer , 2004, Nature Reviews Cancer.

[20]  OUP accepted manuscript , 2022, The Oncologist.